Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

被引：0
|
作者：
Åsa Ericsson
Adam Lundqvist
机构：
[1] Novo Nordisk Scandinavia AB,
[2] IHE,undefined
[3] The Swedish Institute for Health Economics,undefined
来源：
Applied Health Economics and Health Policy | 2017年 / 15卷
关键词：
Liraglutide; Insulin Glargine; Basal Insulin; Insulin Aspart; Insulin Detemir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：237 / 248
页数：11
相关论文
共 50 条
  • [21] The Effect of Fixed-Dose Combination of Insulin Degludec and Liraglutide on Serum Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus
    Pappa, Eleni
    Kostara, Christina
    Tellis, Constantinos
    Tselepis, Alexandros D.
    Bairaktari, Eleni
    Tsimihodimos, Vasilis
    DIABETES, 2020, 69
  • [22] IDegLira, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, Is Efficacious and Safe in Subjects With Type 2 Diabetes: A Large, Randomized Phase 3 Trial
    Buse, John B.
    Gough, Stephen C. L.
    Woo, Vincent
    Rodbard, Helena W.
    Linjawi, Sultan
    Poulsen, Pernille
    Damgaard, Lars H.
    Bode, Bruce W.
    DIABETES, 2013, 62 : A16 - A16
  • [23] Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial
    Kaku, Kohei
    Araki, Eiichi
    Tanizawa, Yukio
    Agner, Bue Ross
    Nishida, Tomoyuki
    Ranthe, Mattis
    Inagaki, Nobuya
    DIABETES OBESITY & METABOLISM, 2019, 21 (12): : 2674 - 2683
  • [24] Efficacy and safety of a combination of insulin degludec plus liraglutide (IDegLira) in people with Type 2 diabetes in India uncontrolled on oral antidiabetic drugs ± basal insulin were similar to the global DUAL phase 3 programme
    Khunti, K.
    Mohan, V.
    Jain, S. M.
    Boesgaard, T. W.
    Begtrup, K.
    Sethi, B. P.
    DIABETIC MEDICINE, 2016, 33 : 61 - 61
  • [25] In patients with Type 2 diabetes, treatment with IDegLira, a combination of insulin degludec and liraglutide, improves both preprandial and postprandial plasma glucose
    Viljoen, A.
    King, A.
    Philis-Tsimikas, A.
    Langbakke, I. H.
    Kvist, K.
    Vilsboll, T.
    DIABETIC MEDICINE, 2015, 32 : 74 - 74
  • [26] Efficacy and safety of IDegLira (combination of insulin degludec plus liraglutide), in insulin-naive patients with type 2 diabetes uncontrolled on GLP-1 receptor agonist (GLP-1RA) therapy
    Linjawi, S.
    Bode, B. W.
    Chaykin, L. B.
    Courreges, J. -P.
    Handelsman, Y.
    Lehmann, L. M.
    Mishra, A.
    Simpson, R. W.
    DIABETOLOGIA, 2015, 58 : S401 - S402
  • [27] Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes
    Lamos, Elizabeth Mary
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (10) : 1225 - 1232
  • [28] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Oya, Junko
    Nakagami, Tomoko
    Hasegawa, Yukiko
    Kondo, Yuichiro
    Katamine, Aki
    Shimizu, Mika
    Kubota, Ryo
    Suda, Rika
    Babazono, Tetsuya
    DIABETOLOGY INTERNATIONAL, 2024, 15 (02) : 237 - 243
  • [29] IDegLira, a novel fixed-ratio combination of insulin degludec and liraglutide, is efficacious and safe in subjects with type 2 diabetes: a large, randomised phase 3 trial
    Gough, S. C. L.
    Buse, J. B.
    Woo, V. C.
    Rodbard, H. W.
    Linjawi, S.
    Poulsen, P.
    Damgaard, L. H.
    Bode, B. W.
    DIABETOLOGIA, 2013, 56 : S96 - S97
  • [30] Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes
    Harris, Stewart
    Abrahamson, Martin J.
    Ceriello, Antonio
    Charpentier, Guillaume
    Evans, Marc
    Lehmann, Roger
    Liebl, Andreas
    Linjawi, Sultan
    Holt, Richard I. G.
    Hosszufalusi, Nora
    Rutten, Guy
    Vilsboll, Tina
    DRUGS, 2020, 80 (02) : 147 - 165
12345